Nektar Therapeutics Retained Earnings
Nektar Therapeutics (NKTR) had Retained Earnings of -$3.85 billion as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$3.85B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$3.81B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$3.76B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$3.72B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$3.85B 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$3.81B 10-Q · filed 2026-05-08 |
| 2025-12-31 | -$3.76B 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$3.72B 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$3.69B 10-Q · filed 2025-08-08 |
| 2025-03-31 | -$3.65B 10-Q · filed 2025-05-09 |
| 2024-12-31 | -$3.60B 10-K · filed 2026-03-13 |
| 2024-09-30 | -$3.60B 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$3.57B 10-Q · filed 2024-08-09 |
| 2024-03-31 | -$3.51B 10-Q · filed 2024-05-10 |
| 2023-12-31 | -$3.48B 10-K · filed 2025-03-14 |
| 2023-09-30 | -$3.44B 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$3.39B 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$3.34B 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$3.20B 10-K · filed 2024-03-05 |
| 2022-09-30 | -$3.14B 10-Q · filed 2022-11-04 |
| 2022-06-30 | -$3.08B 10-Q · filed 2022-08-05 |
| 2022-03-31 | -$2.92B 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$2.83B 10-K · filed 2023-02-28 |
| 2021-09-30 | -$2.69B 10-Q · filed 2021-11-05 |
| 2021-06-30 | -$2.56B 10-Q · filed 2021-08-06 |
| 2021-03-31 | -$2.43B 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$2.31B 10-K · filed 2022-03-01 |
| 2020-09-30 | -$2.19B 10-Q · filed 2020-11-06 |
| 2020-06-30 | -$2.08B 10-Q · filed 2020-08-07 |
| 2020-03-31 | -$2.00B 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$1.86B 10-K · filed 2021-02-26 |
| 2019-09-30 | -$1.75B 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$1.65B 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$1.54B 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$1.42B 10-K · filed 2020-02-28 |
| 2018-09-30 | -$1.33B 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$1.23B 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$2.20B 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$2.12B 10-K · filed 2019-03-01 |
| 2017-09-30 | -$2.08B 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$2.14B 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$2.09B 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$2.02B 10-K · filed 2018-03-01 |
| 2016-09-30 | -$1.98B 10-Q · filed 2016-11-04 |
| 2016-06-30 | -$1.94B 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$1.89B 10-Q · filed 2016-05-04 |
| 2015-12-31 | -$1.87B 10-K · filed 2017-03-01 |
| 2015-09-30 | -$1.81B 10-Q · filed 2015-11-06 |
| 2015-06-30 | -$1.81B 10-Q · filed 2015-08-06 |
| 2015-03-31 | -$1.75B 10-Q · filed 2015-05-01 |
| 2014-12-31 | -$1.79B 10-K · filed 2016-02-29 |
| 2014-09-30 | -$1.74B 10-Q · filed 2014-11-07 |
| 2014-06-30 | -$1.81B 10-Q · filed 2014-08-01 |
| 2014-03-31 | -$1.78B 10-Q · filed 2014-05-08 |
| 2013-12-31 | -$1.73B 10-K · filed 2015-02-26 |
| 2013-09-30 | -$1.68B 10-Q · filed 2013-11-07 |
| 2013-06-30 | -$1.67B 10-Q · filed 2013-08-09 |
| 2013-03-31 | -$1.63B 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$1.57B 10-K · filed 2014-02-27 |
| 2012-09-30 | -$1.52B 10-Q · filed 2012-11-09 |
| 2012-06-30 | -$1.47B 10-Q · filed 2012-08-09 |
| 2012-03-31 | -$1.44B 10-Q · filed 2012-05-04 |
| 2011-12-31 | -$1.40B 10-K · filed 2013-03-01 |
| 2011-09-30 | -$1.36B 10-Q · filed 2011-11-04 |
| 2011-06-30 | -$1.34B 10-Q · filed 2011-08-05 |
| 2011-03-31 | -$1.30B 10-Q · filed 2011-04-29 |
| 2010-12-31 | -$1.26B 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |